Apogee Therapeutics, Inc. Common Stock (APGE) News
Latest headlines that mention APGE, newest first · each headline opens the original publisher
- Last price
- $135.07
- Day change
- -0.01%
- Next earnings
- —
APGE headlines
latest coverageOn June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX)…
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open…
AbbVie announced Monday a $10.9 billion plan to acquire immunology-focused Apogee Therapeutics, sending Apogee stock flying. The post AbbVie Goes On The Offensive With $10.9 Billion Takeover appeared first on Investor's Business Daily .
AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June…
Apogee Therapeutics, which is developing a promising atopic dermatitis drug, saw its stock close nearly 47% higher on Monday.
Also mentioned with APGE
30dHeadlines that tag both tickers
APGE news alerts
Get an alert by email or push when a new headline mentions APGE.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.